Skip to main content
. Author manuscript; available in PMC: 2014 Dec 15.
Published in final edited form as: Cancer Res. 2013 Oct 24;73(24):7254–7264. doi: 10.1158/0008-5472.CAN-13-0750

Figure 4.

Figure 4

MCL tumors contain VEGF-C–expressing macrophages and LEN reduces the number of tumor-associated macrophages. A. Immunofluorescent staining of CD68, a macrophage marker, and VEGF-C in human MCL tumor sections. Arrows indicate VEGF-C+, CD68+ macrophages. Scale bar, 100 μm. B. Immunofluorescent staining of VEGF-C and macrophage markers F4/80 and CD11b in the peripheral regions of sham- and LEN-treated mouse MCL tumors. Arrow indicates a VEGF-C+ macrophage. Scale bar, 100 μm. C. F4/80+, VEGF-C+, and CD11b+ macrophages were quantified in randomly selected areas from the tumor peripheral regions. Data represent the mean ± SD (n = 6, *P < 0.05). D. Expression of human CCL5 in MCL tumor cells was analyzed by real-time PCR. Results represent relative units after normalized to the expression of 18S RNA. Data represent the mean ± SEM (n = 3, ***P < 0.001) from three independent experiments. E. Immunoblot analysis of human CCL5 levels in MCL tumor cells. GAPDH is an internal control. Data are representative of three experiments. F. Macrophage migration measured in response to Mino cell conditioned media (CM) with or without LEN treatment using a transwell assay. Results represent the mean ± SD (n = 9) from three independent experiments. **P < 0.01. G. Macrophage migration in response to sham-treated Mino cell conditioned media with a neutralizing antibody against CCL5 or isotype IgG (control). Results represent the mean ± SD (n = 9) from three independent experiments. *P < 0.05.